NGL Fine-Chem Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
NGLFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
NGL Fine-Chem Limited submitted its Q1 FY26 (quarter ended June 30, 2025) unaudited standalone and consolidated results to the exchanges. On a standalone basis, Profit Before Tax came in at ₹1,183.95 lakhs versus ₹1,178.70 lakhs in Q1 FY25, broadly flat year-on-year. However, standalone Profit After Tax fell sharply to ₹524.06 lakhs from ₹921.91 lakhs a year ago (about 43% decline), driven mainly by a much higher current and deferred tax outflow this quarter. Consolidated PAT was ₹764.41 lakhs against ₹782.57 lakhs in Q1 FY25, holding up better thanks to the 100% subsidiary Macrotech Polychem Private Limited. The statutory auditor, Manek & Associates, issued a clean limited review report with no qualifications, no emphasis of matter, and no exceptional items reported in the quarter.
Operating performance at the pre-tax level was stable, so the headline weakness is largely a tax-timing issue rather than a business deterioration. Still, the standalone PAT drop and the divergence between standalone and consolidated profits may draw investor attention. Clean auditor review and absence of exceptional items keep the filing neutral-to-mildly negative in tone.